Skip to main content
OpenTrials
Completed

NCT Number: NCT04657887

Registry of Patients With Von WilLEbrand Disease Treated With Voncento®

Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of surgical bleeding during 2 years after patient inclusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Von Willebrand Disease Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Blood Platelet Disorders Coagulation Protein Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders von Willebrand Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Besançon, Besançon, France

Loading trial locations.

About this study

Inherited von Willebrand disease (VWD) is considered the most common bleeding disorder. Its prevalence is approximately 1% in the general population but symptomatic patients are rarer (0.01%). It is caused by a partial or total quantitative deficiency (type 1 and type 3) or by a qualitative defect (type 2) of von Willebrand factor (VWF), a large multimeric protein that is required for platelet adhesion and serves as factor VIII (FVIII) carrier. Type 2 VWD is further divided in four subgroups (2A, 2B, 2M, and 2N) that are distinguished according to the nature of the VWF defect. Most patients with type 1 VWD can be treated with the synthetic vasopressin analogue desmopressin (DDAVP; 2-desamino-8-D-arginine vasopressin), whereas patients with type 3 VWD and most patients with type 2 VWD require concentrates containing VWF. Plasma-derived FVIII concentrates, which were initially developed for the treatment of haemophilia, contain large amounts of VWF and are used in patients for whom DDAVP treatment is deemed ineffective or contraindicated. Voncento® (CSL Behring) is a plasma-derived FVIII/VWF concentrate registered in France since 2015 for the treatment and prevention of bleeding events in patients with inherited VWD. OPALE is an observational study describing the use of human coagulation FVIII/VWF concentrate (Voncento®) to treat and prevent bleeding episodes in a French cohort of patients with inherited von Willebrand disease in the real life settings. The aim of the OPALE study is to describe the efficacy and the safety of Voncento® in the prophylaxis and treatment of haemorrhage or surgical bleeding.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients suffering from constitutional von Willebrand disease for whom Desmopressin treatment is deemed ineffective or contraindicated
  • Patients suffering from von Willebrand disease and being treated or having been treated with Voncento® for the treatment of surgical and non-surgical bleeding episodes, the prophylaxis of surgical and non-surgical bleedings
  • Patients with no history or suspicion of inhibitors (judged on previous efficacy)

Exclusion criteria

  • Refusal of the patient or the patient's legal representative to take part in the study;
  • Existence of a contraindication to the use of Voncento® treatment

Treatment and study plan

Voncento®

Biological

Solution for injection

Other names: Biostate

Primary outcomes

  1. Global assessment by the patient and the investigator of the hemostatic efficacy of Voncento® in the management of non-surgical bleeding episodes

    Time frame: Up to 24 months

  2. Number of non-surgical bleeding episodes per year

    Time frame: Up to 24 months

  3. Number of administrations of Voncento® needed to treat a non-surgical bleeding episode and for the long term prophylaxis

    Time frame: Up to 24 months

  4. Total dose of Voncento® (in IU/kg of VWF) needed to treat a non-surgical bleeding episode and for the long term prophylaxis

    Time frame: Up to 24 months

Secondary outcomes

  1. Assessment by the investigator of the hemostatic efficacy of Voncento® during the treatment and the prophylaxis of surgical bleedings and after surgical procedures

    Time frame: Up to 24 months

  2. Number of administrations of Voncento® needed to prevent or treat surgical bleeding episode

    Time frame: Up to 24 months

  3. Total dose of Voncento® (in IU/kg of VWF) needed to prevent or treat surgical bleeding episode

    Time frame: Up to 24 months

  4. Nature and impact of adverse events and in particular serious adverse events, adverse events related to Voncento®

    Time frame: Up to 24 months

  5. Collection of available biological data (ex: FVIII, VWF:Rco, VWF:Ag)

    Time frame: At baseline and up to 24 months

Sponsors and collaborators

Lead sponsor

CSL Behring

Industry

Registry information

Official study title

Observational Registry of Patients With Von WilLEbrand Disease Treated With Voncento®

Acronym: OPALE

Important dates

Study start
2015
Primary completion
2023
Study completion
2023
First posted
Dec 8, 2020
Registry last updated
Apr 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.